论文部分内容阅读
目的 探讨p16基因在乳腺癌发生早期的作用。方法 用免疫组化方法检测 36例乳腺单纯性增生、31例不典型增生、14例导管内癌和 16例浸润性导管癌中p16蛋白的表达 ,用PCR SSCP和DNA测序技术检测上述组织中p16基因突变。结果 p16蛋白在单纯性增生、不典型增生、导管内癌、浸润癌中的表达缺失率分别为 0、16 .1%( 5 /31)、35 .7%( 5 /14 )、43.7%( 7/16 ) ,在 1例不典型增生、1例导管内癌、1例浸润性导管癌中检测p16基因突变。结论 p16蛋白表达缺失出现在乳腺癌发生的早期阶段 ,这种表达异常似乎与p16基因突变无明显关系。
Objective To investigate the role of p16 gene in the early stage of breast cancer. Methods Immunohistochemistry was used to detect the expression of p16 protein in 36 cases of primary breast hyperplasia, 31 cases of atypical hyperplasia, 14 cases of intraductal carcinoma and 16 cases of invasive ductal carcinoma. The expression of p16 protein was detected by PCR SSCP and DNA sequencing. Gene mutation. Results The loss rates of p16 protein in simple hyperplasia, atypical hyperplasia, intraductal carcinoma and invasive carcinoma were 0,16. 1% (5/31), 35.7% (5/14) and 43.7% 7/16). The p16 gene mutation was detected in one case of atypical hyperplasia, one case of ductal carcinoma and one case of invasive ductal carcinoma. Conclusion The loss of p16 protein expression occurs in the early stage of breast cancer. The abnormal expression seems to be not related to the mutation of p16 gene.